Food Allergy Pipeline Report 2023: Analysis of Clinical Trials, Therapeutic Assessment, Mechanism of Action, Route of Administration, and Drugs by DelveInsight

Food Allergy Pipeline

A food allergy occurs when the body’s immune system sees a certain food as harmful and reacts by causing symptoms. This is an allergic reaction. Foods that cause allergic reactions are allergens.

“Food Allergy Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Food Allergy Market.

The Food Allergy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Food Allergy Pipeline Report:

• Companies across the globe are diligently working toward developing novel Food Allergy treatment therapies with a considerable amount of success over the years. Food Allergy Key players such as – Intrommune Therapeutics, Xencor, Vedanta Biosciences, Aravax, Alladapt Immunotherapeutics, Regeneron, DBV Technologies, Novartis AG, Camallergy, Genentech, and others, are developing therapies for the Food Allergy treatment 

• Food Allergy Emerging therapies such as – INT301, AIMab7195, VE416, PVX-108, ADP101, Dupilumab, DBV 135, Ligelizumab, CA002, Omalizumab, and others are expected to have a significant impact on the Food Allergy market in the coming years.   
• In November 2022, From the 2022 ACAAI meeting in Louisville, KY, Medpage reported on omalizumab (Xolair) which isproving to be an effective therapy for patients with multiple food allergies according to an ongoing phase 3 study named OUtMATCH
• US FDA has granted Breakthrough Therapy Designation for Xolair (omalizumab) for the prevention of severe allergic reactions following accidental exposure to 1 or more foods in patients with allergies.

Route of Administration

Food Allergy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Inhalation
• Inhalation/Intravenous/Oral
• Intranasal
• Intravenous
• Intravenous/ Subcutaneous
• NA
• Oral
• Oral/intranasal/subcutaneous
• Parenteral
• Subcutaneous

Molecule Type

Products have been categorized under various Molecule types, such as

• Antibody
• Antisense oligonucleotides
• Immunotherapy
• Monoclonal antibody
• Peptides
• Protein
• Recombinant protein
• Small molecule
• Stem Cell
• Vaccine

Food Allergy Pipeline Therapeutics Assessment

• Food Allergy Assessment by Product Type
• Food Allergy By Stage and Product Type
• Food Allergy Assessment by Route of Administration
• Food Allergy By Stage and Route of Administration
• Food Allergy Assessment by Molecule Type
• Food Allergy by Stage and Molecule Type

DelveInsight’s Food Allergy Report covers around products under different phases of clinical development like-

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Download Sample PDF Report to know more about Food Allergy drugs and therapies

Some of the key companies in the Food Allergy Therapeutics Market include:

Key companies developing therapies for Food Allergy treatment are – Merck & Co, AstraZeneca, Mabylon, GI Innovation, Aimmune Therapeutics, Inc, Novartis Pharmaceuticals, DBV Technologies, InnoUp Farma S.L., COUR Pharmaceutical Development Company Inc, Vedanta Biosciences, Inc, Regeneron Pharmaceuticals, Genentech, Inc, Camallergy, Aravax, Inimmune, Prota therapeutics, Intrommune Therapeutics, Alladapt Immunotherapeutics, Siolta Therapeutics, IgGenix,  Rho Federal Systems Division, Inc, and many others.

Emerging Food Allergy Drugs Under Different Phases of Clinical Development Include:

• INT301 Intrommune Therapeutics
• AIMab7195 Xencor
• Viaskin Peanut: DBV technologies
• VE416 Vedanta Biosciences
• Omalizumab: Genentech
• Dupilumab: Regeneron Pharmaceuticals
• PVX-108 Aravax
• ADP101: Alladapt Immunotherapeutics
• ADP101 Alladapt Immunotherapeutics
• Dupilumab Regeneron
• DBV 135 DBV Technologies
• Ligelizumab Novartis AG
• CA002 Camallergy
• Omalizumab Genentech

Get a Free Sample PDF Report to know more about Food Allergy Pipeline Therapeutic Assessment- https://www.delveinsight.com/sample-request/food-allergy-pipeline-insight

Food Allergy Pipeline Analysis:

The Food Allergy pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Food Allergy with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Food Allergy Treatment.
• Food Allergy key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Food Allergy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Food Allergy market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Further Food Allergy product details are provided in the report. Download the Food Allergy pipeline report to learn more about the emerging Food Allergy therapies

Food Allergy Pipeline Market Drivers

• Increasing prevalence of food allergies
• Growth in commercial and scientific activities for research and development

Food Allergy Pipeline Market Barriers

• Lack of Public awareness
• Accurate diagnosis of food allergies is critical

Scope of Food Allergy Pipeline Drug Insight    

• Coverage: Global
• Key Food Allergy Companies: Intrommune Therapeutics, Xencor, Vedanta Biosciences, Aravax, Alladapt Immunotherapeutics, Regeneron, DBV Technologies, Novartis AG, Camallergy, Genentech, and others
• Key Food Allergy Therapies: INT301, AIMab7195, VE416, PVX-108, ADP101, Dupilumab, DBV 135, Ligelizumab, CA002, Omalizumab, and others
• Food Allergy Therapeutic Assessment: Food Allergy current marketed and Food Allergy emerging therapies
• Food Allergy Market Dynamics: Food Allergy market drivers and Food Allergy market barriers 

Request for Sample PDF Report for Food Allergy Pipeline Assessment and clinical trials

Table of Contents

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/conference-coverage-services